220 related articles for article (PubMed ID: 38599220)
21. Ticagrelor With or Without Aspirin After Complex PCI.
Dangas G; Baber U; Sharma S; Giustino G; Mehta S; Cohen DJ; Angiolillo DJ; Sartori S; Chandiramani R; Briguori C; Dudek D; Escaned J; Huber K; Collier T; Kornowski R; Kunadian V; Kaul U; Oldroyd K; Sardella G; Shlofmitz R; Witzenbichler B; Ya-Ling H; Pocock S; Gibson CM; Mehran R
J Am Coll Cardiol; 2020 May; 75(19):2414-2424. PubMed ID: 32240761
[TBL] [Abstract][Full Text] [Related]
22. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
23. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
Baber U; Jang Y; Oliva A; Cao D; Vogel B; Dangas G; Sartori S; Spirito A; Smith KF; Branca M; Collier T; Pocock S; Valgimigli M; Kim BK; Hong MK; Mehran R
Circulation; 2024 Feb; 149(8):574-584. PubMed ID: 37870970
[TBL] [Abstract][Full Text] [Related]
24. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
[TBL] [Abstract][Full Text] [Related]
25. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Baber U; Dangas G; Cohen DJ; Gibson CM; Mehta SR; Angiolillo DJ; Pocock SJ; Krucoff MW; Kastrati A; Ohman EM; Steg PG; Badimon J; Zafar MU; Chandrasekhar J; Sartori S; Aquino M; Mehran R
Am Heart J; 2016 Dec; 182():125-134. PubMed ID: 27914492
[TBL] [Abstract][Full Text] [Related]
26. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
[TBL] [Abstract][Full Text] [Related]
27. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
[TBL] [Abstract][Full Text] [Related]
28. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial.
Li Y; Jing Q; Wang B; Wang X; Li J; Qiao S; Chen S; Angiolillo DJ; Han Y
Am Heart J; 2020 Oct; 228():1-7. PubMed ID: 32739652
[TBL] [Abstract][Full Text] [Related]
29. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
Guimarães PO; Franken M; Tavares CAM; Silveira FS; Antunes MO; Bergo RR; Joaquim RM; Hirai JCS; Andrade PB; Pitta FG; Mariani J; Nascimento BR; de Paula JET; Silveira MS; Costa TAO; Dall'Orto FTC; Serpa RG; Sampaio FBA; Ohe LN; Mangione FM; Furtado RHM; Sarmento-Leite R; Monfardini F; Assis SRL; Nicolau JC; Sposito AC; Lopes RD; Onuma Y; Valgimigli M; Angiolillo DJ; Serruys PW; Berwanger O; Bacal F; Lemos PA
EuroIntervention; 2023 Jul; 19(4):e323-e329. PubMed ID: 37306039
[TBL] [Abstract][Full Text] [Related]
30. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
[TBL] [Abstract][Full Text] [Related]
31. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Vranckx P; Valgimigli M; Windecker S; Steg PG; Hamm C; Jüni P; Garcia-Garcia HM; van Es GA; Serruys PW
EuroIntervention; 2016 Nov; 12(10):1239-1245. PubMed ID: 26606735
[TBL] [Abstract][Full Text] [Related]
32. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial.
Vogel B; Baber U; Cohen DJ; Sartori S; Sharma SK; Angiolillo DJ; Farhan S; Goel R; Zhang Z; Briguori C; Collier T; Dangas G; Dudek D; Escaned J; Gil R; Han YL; Kaul U; Kornowski R; Krucoff MW; Kunadian V; Mehta SR; Moliterno D; Ohman EM; Sardella G; Witzenbichler B; Gibson CM; Pocock S; Huber K; Mehran R
JAMA Cardiol; 2021 Sep; 6(9):1032-1041. PubMed ID: 33991416
[TBL] [Abstract][Full Text] [Related]
33. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial.
Tomaniak M; Chichareon P; Onuma Y; Deliargyris EN; Takahashi K; Kogame N; Modolo R; Chang CC; Rademaker-Havinga T; Storey RF; Dangas GD; Bhatt DL; Angiolillo DJ; Hamm C; Valgimigli M; Windecker S; Steg PG; Vranckx P; Serruys PW;
JAMA Cardiol; 2019 Nov; 4(11):1092-1101. PubMed ID: 31557763
[TBL] [Abstract][Full Text] [Related]
34. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Cuisset T; Deharo P; Quilici J; Johnson TW; Deffarges S; Bassez C; Bonnet G; Fourcade L; Mouret JP; Lambert M; Verdier V; Morange PE; Alessi MC; Bonnet JL
Eur Heart J; 2017 Nov; 38(41):3070-3078. PubMed ID: 28510646
[TBL] [Abstract][Full Text] [Related]
35. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
[TBL] [Abstract][Full Text] [Related]
36. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
[TBL] [Abstract][Full Text] [Related]
37. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial.
Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644
[TBL] [Abstract][Full Text] [Related]
38. Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention.
Shin ES; Her AY; Kim B; Hahn JY; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
J Korean Med Sci; 2023 Nov; 38(45):e383. PubMed ID: 37987108
[TBL] [Abstract][Full Text] [Related]
39. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention.
Angiolillo DJ; Baber U; Sartori S; Briguori C; Dangas G; Cohen DJ; Mehta SR; Gibson CM; Chandiramani R; Huber K; Kornowski R; Weisz G; Kunadian V; Oldroyd KG; Ya-Ling H; Kaul U; Witzenbichler B; Dudek D; Sardella G; Escaned J; Sharma S; Shlofmitz RA; Collier T; Pocock S; Mehran R
J Am Coll Cardiol; 2020 May; 75(19):2403-2413. PubMed ID: 32240760
[TBL] [Abstract][Full Text] [Related]
40. Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial.
Krucoff M; Spirito A; Baber U; Sartori S; Angiolillo DJ; Briguori C; Cohen DJ; Collier T; Dangas G; Dudek D; Escaned J; Gibson CM; Han YL; Huber K; Kastrati A; Kaul U; Kornowski R; Kunadian V; Vogel B; Mehta SR; Moliterno D; Sardella G; Shlofmitz RA; Sharma S; Steg PG; Pocock S; Mehran R
Am Heart J; 2024 Jun; 272():11-22. PubMed ID: 38458371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
